From GlobeNewswire: 2025-04-15 08:19:00

Biomerica, Inc. reported a 10% increase in total revenue year-over-year, achieving improved gross margins and early cost savings targets. Their Fortel® PSA Screening Test was approved by the UAE Ministry of Health & Prevention, while inFoods® IBS clinical trial results were published in Gastroenterology, showing reductions in abdominal pain and bloating. Additionally, Biomerica achieved CE-IVDR certification for food intolerance products targeting Ulcerative Colitis. They reached their full-year cost savings target nine months ahead of schedule, delivering $1.1 million in savings. In the third quarter of fiscal 2025, Biomerica reported a 10% increase in net sales to $1.10 million, improved gross margin to 2%, and decreased operating expenses by 37% to $1.20 million. Operating loss improved to ($1.20) million, and net loss narrowed to ($1.20) million, representing a 37% improvement year-over-year. Biomerica’s cash and cash equivalents totaled $3.06 million, with a reduced quarterly cash burn of approximately $800,000 compared to the previous year, showing a 55% reduction. CEO Zack Irani highlighted the company’s progress in strengthening its financial foundation and cost-saving initiatives.



Read more at GlobeNewswire:: Biomerica Reports Third Quarter Fiscal 2025 Financial